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Backgrounds: While previous meta-analysis have investigated the efficacy of cilostazol in the secondary prevention
of ischemic stroke, they were criticized for their methodology, which confused the acute and chronic phases of
stroke. We present a new systematic review, which differs from previous meta-analysis by distinguishing between
the different phases of stroke, and includes two new randomized, controlled trials (RCTs).
Methods: All RCTs investigating the effect of cilostazol on secondary prevention of ischemic stroke were obtained.
Outcomes were analyzed by Review Manager, including recurrence of cerebral infarction (ROCI), hemorrhage stroke
or subarachnoid hemorrhage (HSSH), all-cause death (ACD), and modified Rankin Scale score (mRS). The Grading of
Recommendations Assessment, Development and Evaluation (GRADE) assessed the quality of the evidence.
Results: 5491 patients from six studies were included in the current study. In secondary prevention of ischemic
stroke in chronic phase, cilostazol was associated with a 47% reduction in ROCI (relative risk [RR] 0.53, 95%
confidence interval [CI] 0.34 to 0.81, p = 0.003), while no significant difference in HSSH and ACD compared with
placebo; and 71% reduction in HSSH (RR 0.29, 95% CI 0.15 to 0.56, p = 0.0002) compared with aspirin, but not in
ROCI and ACD. In the secondary prevention of ischemic stroke in acute phase, cilostazol did not show any effect in
the ROCI, HSSH, ACD and mRS compared to placebo or aspirin. The quality of the evidence from chronic phase was
high or moderate, and those from acute phase were moderate or low when analyzed by GRADE approach.
Conclusion: Cilostazol provided a protective effect in the secondary prevention of the chronic phase of ischemic
stroke.
Keywords: Acute Phase, Chronic phase, Cilostazol, Meta-analysis, StrokeBackground
Stroke accounts for 10% of all deaths worldwide [1], and
is the second leading cause of mortality in China [2]. Re-
curring strokes in approximately 30% of patients showed
more severe consequences than primary stroke, usually
leading to dementia and death [3]. Thus, secondary pre-
vention in high-risk patients with a previous stroke be-
comes extremely important. Among the various medical* Correspondence: saintchan@sina.com
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unless otherwise stated.managements, aspirin plays a pivotal role in the se-
condary prevention of stroke because of its antiplatelet
efficacy [4]. However, this efficacy has prominent race-
ethnic differences, a recent study reported that Asians
have a higher risk of recurrent ischemic and hemor-
rhagic stroke in the secondary stroke prevention phase
[5]. Besides systemic hemorrhagic events, common side
effects including dyspepsia, abdominal pain, and gastric
ulcers have also limited its clinical application [6,7]. It is
therefore necessary to develop an effective new drug
with a lower incidence of side effects for aspirin into-
lerant populations. Cilostazol, an antiplatelet agent with
selectively inhibiting phosphodiesterase III, is such ans is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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cellular cyclic adenosine monophosphate (cAMP) and
inhibits platelet aggregation, but also improves endothe-
lial function and inhibits the proliferation of arterial
smooth muscle cells [9]. Furthermore, several random-
ized controlled trials (RCTs) indicate that cilostazol had
lessintracranial hemorrhage risks, compared with aspirin
in the secondary prevention of the stroke [2,4,9,10].
Previous systematic reviews and meta-analysis of RCTs
determined whether cilostazol reduces morbidity and mor-
tality compared with aspirin for the secondary prevention
of stroke [11,12]. However, these meta-analysis were in-
complete in several respects. The major criticism was its
methodology that confused the acute and chronic phases
of stroke. It has been confirmed that the acute phase of
reperfusion injury exists in animal models of ischemic
stroke, which plays an important role in the microcircula-
tion levels [13]. It has also been confirmed that 20% to
40% of all patients in acute phase have aprogressive
worsening of clinical and/or radiologic features even with
currently available treatments [14]. Furthermore, recent
studies have demonstrated that cilostazol might be a pro-
tective agent in the secondary prevention of the chronic
phases of stroke [2,4,9,15]. But the benefit of cilostazol in
the prevention of stroke was controversial [10,16]. The
minor criticisms contributing to the unsoundness of previ-
ous meta-analysis included the lack of data pertaining to
the efficacy of cilostazol compared with a placebo. A re-
cent RCT reported negative results of cilostazol against
acute progressing stroke [16], which differed from a pre-
vious RCT [10] and might reverse the conclusion of the
previous meta-analysis. Hence, we present a new sys-
tematic review, which differs from the previous systematic
reviews in their methodology and inclusion of ano-
ther two new RCTs. Moreover, the Grading of Recom-
mendations Assessment, Development and Evaluation




At the beginning of this project, a study protocol was
drafted following the Cochrane Collaboration format [20].
Eligibility criteria
The present systematic review only included studies
which met the following criteria: 1) study type: RCTs;
2) language restriction: only English studies were re-
viewed; 3) participants: adult patients suffered ischemic
stroke; 3) intervention: cilostazol; 4) comparator: aspirin
or placebo; 5) outcomes: recurrence of cerebral infarc-
tion (ROCI), hemorrhage stroke or subarachnoid he-
morrhage (HSSH), and all-cause death (ACD). Exclusion
criteria: 1) study types: case control study, cohort study,and retrospective study; 2) withdraw rate: > 20%; 3) par-
ticipants: < 18 years.
Search strategy and information sources
Two of the authors (LGS and JLP) independently
searched the Medline database up to March 2014 for the
combination of the variables “cilostazol” AND “stroke”.
The search was limited to clinical studies and matched
the titles and abstracts of studies. Moreover, we searched
for all relevant RCT or meta-analysis studies in the
Embase, Cochrane Library and the Cochrane Central
Register of Controlled Trials published between Jan
1980 and March 2014. To insure all relevant studies had
been included in this systematic review, besides the elec-
tronic database search, reference lists from RCTs and
systematic reviews were manually screened. The appen-
dices include details of the search strategies (Appendix).
Study selection and data collection
We included RCTs that assessed the efficacy and accept-
ability of cilostazol compared with placebo or aspirin
treatment in patients with the history of stroke, as diag-
nosed by computed tomography (CT) or magnetic reso-
nance imaging (MRI). All patients were recruited with the
results for the secondary prevention of ischemic stroke in
acute and chronic phases as separate subgroups. The
acute phase of ischemic stroke was diagnosed when the
patient suffered a cerebral infarction within 48 hours prior
to participation in the trial without serious complications,
and the chronic phase was defined from 1 to 6 months.
The outcomes included as the following: ROCI, HSSH,
ACD, and modified Rankin Scale score (mRS), all based
on intention-to-treat datasets.
After reading all included RCT articles, we extracted
the following data, which were described in all studies:
country, single or multiple therapeutic centers, inclusion
criteria for the participants, general information of the
patients (age and gender), and therapeutic schedule
(usage of the drugs, doses, and duration). The four out-
comes were also selected from each trial.
Risk of bias and quality assessment
The Cochrane Collaboration tool was used in this sys-
tematic review to assess the risk of bias in each included
RCT study. Two review authors (LGS and JLP) were
independently assessed for methodological quality by the
following six items: random sequence generation and al-
location concealment (selection bias), blinding of par-
ticipants and personnel (performance bias), blinding of
outcome assessment (detection bias), incomplete out-
come data (attrition bias), selective reporting (reporting
bias) and other potential biases. For each item, the
table provides a description and judgment rated as
“low”, “unclear” or “high” risk of bias. The risk of bias plot
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GRADE approach was used to assess the quality of the evi-
dence. In this approach, we mainly assessed five items, in-
cluding risk of bias, inconsistency, indirectness,
imprecision and publication bias, which can affect the
quality of evidence. For each item, the table provides a
judgment criteria rated as “high, moderate, low or very
low”. After assessment of the evidence, GRADE pro 3.6
software created an evidence profiletable.Summary measures and synthesis of results
Data was processed in Review Manager 5.2 from the
Cochrane Collaboration. Dichotomous outcomes were an-
alyzed as the risk ratio (RR; 95% confidence interval [CI])
using the Mantel–Haenszel technique and a fixed effect
model. Statistical heterogeneity was estimated by the
I2statistic as follows: I2 < 30% means “low heterogeneity”,
I2 = 30% to 50% denotes “moderate heterogeneity”, and
I2 > 50% represents “substantial heterogeneity”. Tests were
two-tailed and a p value less than 0.05 was considered to
be significant for all analysis.Results
We retrieved 763 records after the initial search strategy
that scanned for title and abstract. A further 753 records
were excluded either for unrelated to the study question
or not a RCT, resulting in 10 papers for further assess-
ment. Another 4 records have been excluded from this
analysis for the following reasons: meta-analysis record,
cilostazol and aspirin combined therapy, irrelevant out-
comes, and duplicate data. Finally, six RCTs on the basisFigure 1 Study search, selection and inclusion process.of the inclusion criteria (Figure 1) were included with a
total of 5491 patients.
Study characteristics
The main characteristics and outcome events of the in-
cluded RCT studies are listed in Table 1. The six RCTs,
combined, enrolled 5491 patients including 965 patients
in acute phase and 4526 patients in chronic phase of
ischemic stroke. All the patients come from an Asian
background, such as Japan, China, and Korea. The age
of patients ranged from 59.4 to 66.6 years old. The
follow-up time for the acute phase of ischemic stroke
was 3 months, with the follow-up time for the chronic
phase ranging from 1 to 5 years.
Outcomes analysis
For all analysis pertaining to efficacy and acceptability,
no evidence exists for the between-study of heterogene-
ities assessed by Cochrane I2 statistic (data not shown).
No significant publication bias was shown in the funnel
plots (data not shown).
The efficacy and safety of cilostazol in chronic phase
Results for this analysis and the quality of this evidence
were presented in Table 2. For the analysis of the efficacy
and safety of cilostazol in chronic phase, all 4526 pa-
tients from all 4 studies were available (1067 patients
from 1 study randomized to cilostazol or placebo, and
3459 patients from 3 studies to cilostazol or aspirin). In
the placebo-controlled study, cilostazol therapy reduced
the ROCI by 47% (RR 0.53, 95% CI 0.34 to 0.81,
p = 0.003), and showed similar incidence in the HSSH
Table 1 Characteristics of the included studies and outcome events
Articles Country Therapeutic
centre
Inclusion criteria Drugs Age Male
percentage (%)
Dose ITT population Duration ROCI % HSSH % mRS
0–1%
ACD %
Gotoh 2000 Japan 183 clinical
institutes
Cerebral infarction
at 1 to 6 months
Cilostazol 65.2 (NC) 64.6 100 mg twice daily 533/1067 1-5 years 5.7 0.8 / 1.7
Placebo 65.1 (NC) 60.8 NC 534/1067 10.8 1.3 / 1.9
Huang 2008 China Multiple
center trial
Cerebral infarction
at 1 to 6 months
Cilostazol 60.14 (10.05) 66.9 NC 360/719 1-1.5 years 3.1 0.3 / 0.8
Aspirin 60.31 (9.71) 70.5 NC 359/719 4.2 1.9 / 1.4
Guo 2009 China Single
center trail
Cerebral infarction
at 1 to 6 months
Cilostazol 59.44 (10.63) 35.3 100 mg twice daily 34/68 1 year 5.9 0 / 0
Aspirin 62.06 (11.12) 35.3 100 mgonce daily 34/68 2.9 2.9 / 5.9





Cilostazol 63.5 (9.2) 71.7 100 mg twice daily 1337/2672 1–5 years 5.4 0.7 / 1.0
Aspirin 63.4 (9.0) 71.7 81 mg once daily 1335/2672 6.6 2.3 / 1.0
Lee 2011 Korea 12 clinical
institutes
Cerebral infarction
within 48 h of onset
Cilostazol 63 (12) 64.1 100 mg twice daily 231/458 90 days 2.2 0 56.3 0.4
Aspirin 63 (12) 58.6 300 mg/day 227/458 4.0 0.9 56.8 0
Shimizu 2013 Japan 55 clinical
institutes
Cerebral infarction
within 48 h of onset
Cilostazol 66.2 (9.4) 65.7 100 mg twice daily 251/507 90 days 1.2 0.8 74.5 0
Placebo 66.6 (8.9) 68.4 NC 256/507 1.6 0.8 72.7 0











Table 2 Analysis and quality of the evidence using GRADE for efficacy and safety outcomes
Outcomes No of participants (studies) Relative effect (95% CI) Risk of bias Inconsistency Indirectness Imprecision Publication bias Quality of the evidence (GRADE)
1. Subgroup Analysis - Cilostazol compared to Aspirin for the Secondary Prevention of Stroke in the Chronic phase
ROCI 3459 (3 studies) RR 0.82 (0.62 to 1.08) No serious No serious No serious No serious Undetected ⊕⊕⊕⊕ high
HSSH 3459 (3 studies) RR 0.29 (0.15 to 0.56)*** No serious No serious No serious No serious Undetected ⊕⊕⊕⊕ high
ACD 3459 (3 studies) RR 0.80 (0.42 to 1.53) No serious No serious No serious No serious Undetected ⊕⊕⊕⊕ high
2. Sensitivity Analysis - Cilostazol compared to Aspirin for the Secondary Prevention of Stroke in the Chronic phase without CSPS 2 trial
ROCI 787 (2 studies) RR 0.81 (0.40 to 1.66) Serious1 No serious No serious No serious Undetected ⊕⊕⊕⊝ moderate
HSSH 787 (2 studies) RR 0.18 (0.03 to 0.99)* Serious1 No serious No serious No serious Undetected ⊕⊕⊕⊝ moderate
ACD 787 (2 studies) RR 0.47 (0.13 to 1.64) Serious1 No serious No serious No serious Undetected ⊕⊕⊕⊝ moderate
3. Sensitivity Analysis - Cilostazol compared to Aspirin for the Secondary Prevention of Stroke in the Chronic phase without Guo-2009 trail
ROCI 3391 (2 studies) RR 0.80 (0.61 to 1.07) No serious No serious No serious No serious Undetected ⊕⊕⊕⊕ high
HSSH 3391 (2 studies) RR 0.29 (0.15 to 0.56)*** No serious No serious No serious No serious Undetected ⊕⊕⊕⊕ high
ACD 3391 (2 studies) RR 0.89 (0.45 to 1.73) No serious No serious No serious No serious Undetected ⊕⊕⊕⊕ high
ROCI: Recurrence of Cerebral Infarction; HSSH: Hemorrhage Stroke or Subarachnoid Hemorrhage; ACD: All Case Death; CI: Confidence Interval; RR: Risk Ratio; *P < 0.05; ***P < 0.001.
1Potential bias because of unclear of blinding.
GRADE Working Group grades of evidence:
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
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0.90, 95% CI 0.37 to 2.20, p = 0.82). These data were not
shown in the tables or figures. In the aspirin-controlled
studies, cilostazol therapy was associated with an in-
significant 18% reduction in the ROCI (RR 0.82, 95% CI
0.62 to 1.08, p = 0.15; Figure 2A), and a 71% reduction in
the HSSH (RR 0.29, 95% CI 0.15 to 0.56, p = 0.0002;
Figure 2B) with no significant difference in the ACD (RR
0.80, 95% CI 0.42 to 1.53, p = 0.51; Figure 2C). In order
to detect whether the consolidated results were in-
fluenced by one study with a large population [9], we
performed the sensitivity analysis to confirm that the re-
sults were stable (Table 2).
The efficacy and safety of cilostazol in acute phase
For the analysis of the efficacy and safety of cilostazol in
acute phase, 965 patients from 2 studies were included
(507 patients from 1 study randomized to cilostazol or
placebo, and 458 patients from 1 study to cilostazol or as-
pirin). In the placebo-controlled study, cilostazol therapy
showed no significant efficacy in the ROCI (RR 0.76, 95%
CI 0.17 to 3.38, p = 0.72), and a similar result in the HSSH
(RR 1.02, 95% CI 0.14 to 7.18, p = 0.98). In the aspirin-
controlled study, cilostazol therapy was associated with noFigure 2 Pooled relative risk of stroke recurrence,hemorrhagic stroke
insecondary prevention of stroke. (A) Pooled relative risk estimates on r
hemorrhage stroke or subarachnoid hemorrhage. (C) Pooled relative risk es
relative risk (95% confidence interval) for all patients together.significant efficacy in the ROCI (RR 0.55, 95% CI 0.19 to
1.60, p = 0.27), and showed the similar incidence in the
HSSH (RR 0.20, 95% CI 0.01 to 4.12, p = 0.30) and ACD
(RR 2.95, 95% CI 0.12 to 72, p = 0.51). No significant dif-
ference existed between cilostazol therapy and placebo or
aspirin groups in the mRS (data not shown).
Risk of the bias
For allocation concealment, risk of bias was high in one
study [16] and unclear in another one [4]. For blinding
of participants and personnel, risk of bias was high in
one study [16]. For blinding of outcomes assessment,
risk of bias was high in one study [16]. Except these four
items, no high risk of bias was observed in any of the
other items (Figure 3).
Discussion
The present systematic review and meta-analysis, inclu-
ding 6 RCTs in 5491 patients, evaluated the efficacy and
acceptability of cilostazol for the secondary prevention of
ischemic stroke. Our results suggest that cilostazol therapy
leads to a significant reduction in ROCI compared to pla-
cebo, and a lower incidence of the HSSH compared with
aspirin in the chronic phase. While in acute phase,and all cause death between cilosatzol and aspirin groups
ecurrence of cerebral infarction. (B) Pooled relative risk estimates on
timates on all cause death. The diamond indicates the estimated
Figure 3 Risk of bias: a summary table for each risk of bias items for each study.
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cebo, and had a similar incidence of the HSSH to aspirin
therapy. These findings support that cilostazol may be an
advisable therapeutic alternative for aspirin in the secon-
dary prevention of the chronic phase of ischemic stroke.
Quality of the evidence for the outcomes from chronic
phase studies assessed by GRADE was high or moderate,
which provides a sufficient confidence at the application
of cilostazol in clinical practice.
Compared with the methodology of the previous meta-
analysis [11,12], the present systematic review explored the
scope of cilostazol application for the secondary prevention
of ischemic stroke. First, we defined the acute and chronic
phases of ischemic stroke according to the onset-to-
treatment time as follows: i) acute phase refers to pa-
tients having had an ischemic stroke within the preceding
48 hours; ii) the definition of chronic phase refers that pa-
tients were enrolled 1 to 6 months after ischemic stroke.
The previous meta-analysis [11,12], did not distinguish bet-
ween the acute and chronic phases. The present systematic
review showed that cilostazol had controversial efficacy in
the prevention of acute ischemic stroke. It is mainly due to
the starting treatment time after onset. Many of the pre-
vious studies have reported that approximately 20%-37% of
patients with acute ischemic stroke worsened gradually or
stepwise after onset [21,22]. Among these patients, 58%-
82% deteriorated progressively during the first 24 hours
[23-25]. Hence, patients included within the first 24 hours
of the Shimizu et al. [10] study may have progressed to a
worse condition, which influenced the efficacy of cilostazol.
In cases relating to thechronic phase of ischemic stroke,
cilostazol showed a significant beneficial effect, which
was consistent with the previous studies [2,4,9,11,12]. Se-
cond, in the previous meta-analysis [11,12], only aspirin-
controlled RCTs were included to assess the efficacy ofthe cilostazol, which concluded that no significant dif-
ference existed in ROCI between cilostazol and aspirin. In
the present systematic review, we have included both as-
pirin and placebo-controlled RCTs, which resulted in a
more comprehensive conclusion that cilostazol has a def-
inite effect in the ROCI, but not better than aspirin. Fur-
thermore, we concluded that cilostazol is safer than
aspirin in the HSSH, which was similar to the placebo.
Third, we used a fixed-effects approach in meta-analysis
where data did not indicate heterogeneity.
Current stroke guidelines from the American Stroke
Association (ASA) and American Heart Association
(AHA), recommend aspirin, clopidogrel, or aspirin plus
extended-release dipyridamole as first-line options for sec-
ondary prevention of ischemic events (Class IIa, Level of
Evidence A) [26]. Aspirin has a wide dose range from 50 to
1300 mg/d to prevent the reoccurrence of stroke [27].
However, both high- or low-dose aspirin may cause intra-
cranial hemorrhagic events, which could limit its clinical
application [28]. Cilostazol, a novel antiplatelet drug,
prevents the recurrence of ischemic stroke through its
antiplatelet effects [8], vasodilation, inhibition of vascular
smooth muscle cell growth, and neuroprotection. Several
randomized, multicentered trials demonstrated the prevent-
able effect of cilostazol in patients with a previous stroke.
According to the Cilostazol Stroke Prevention Study, pa-
tients with a prior stroke, who were allocated to cilostazol
100 mg twice daily or placebo, showed that cilostazol
therapy reached a significant 58.3% reduction in ROCI,
with no clinically significant adverse reactions [15]. Three
other RCTs compared with aspirin show that cilostazol not
only had similar therapeutic effects with aspirin in the
ROCI, but also had a significant reduction in the HSSH
[2,4,9]. In the animal studies, cilostazol showed a better ef-
fect than aspirin in the reduction of brain damage after
Shi et al. BMC Neurology  (2014) 14:251 Page 8 of 10ischemic stroke though suppressing disruption of the mi-
crovasculature and increasing the residual perfusion of
microcirculation [29,30]. A pilot study, reported that pa-
tients treated with combined therapy had less neurological
deterioration and a more favorable functional status than
those treated with aspirin alone in secondary prevention of
acute ischemic stroke [31]. Another double-blind multicen-
ter trial containing 244 aspirin subjects with ischemic
stroke who were randomly assigned to receive cilostazol
100 mg twice daily or placebo, observed a trend toward en-
hanced antiplatelet effects when cilostazol was added to as-
pirin in ischemic stroke patients [32]. It should be noted
however, that cilostazol was more likely to cause several ad-
verse events other than intracranial hematoma in com-
parison with aspirin [9]. The most common adverse events
were put in descending order of occurrence as follows:
headache, diarrhea, palpitations, dizziness, and tachycardia
[9]. These findings supported that cilostazol is an alternative
drug of aspirin but still needs large, randomized, multicen-
tered trials to confirm the efficacy and safety of cilostazol.
In the present review, several factors may affect the com-
bining of data, despite the statistics showing a low hetero-
geneity. For the treatment duration, 2 studies [9,15]
followed up for 1–5 years, while another two studies [2,4]
were 1–1.5 years. However, this difference in the date of
treatment may only play a minor role because the Kaplan-
Meier curves for the accumulation of primary endpoints
showed a steady trend after 400 days [2]. For the stroke eti-
ologies, the most common type was lacunar infarction
followed by atherothrombotic infarction in the included
studies. Three studies provided similar findings in about
65% -75% proportion of lacunar infarction, and no signifi-
cant difference existed between cilostazol and controlled
groups [9,15,16]. Another three studies lacked data regard-
ing stroke etiologies [2,4,10], which might affect the com-
bining of data to some degree. For the different vascular
risk factors, a previous review has indicated that hyperten-
sion, diebetes, and hyperlipidemia maybe the main causes
to influence the efficacy of secondary prevention [33]. In
the present review, all six included studies recruited ap-
proximately 70% hypertension, 30% diebetes, and 30%
hyperlipidemia. Only one study showed significant diffe-
rences in systolic blood pressure between cliostazol and
controlled groups [9]. Although the authors clarified that
no interaction existed between treatment group and meas-
urement time-points for systolic or diastolic blood pressure,
the results of sensitivity analysis, without this study, showed
that the difference became smaller but did not reverse the
results (Table 2).
Several limitations of the present study should be con-
sidered. First, the present meta-analysis only included 4
studies for the chronic phase of ischemic stroke, and 2
studies for acute stroke. The number of studies is small,
which may cause reporting bias. The result of secondaryprevention for chronic phase of ischemic stroke was based
on one placebo-controlled RCT, which was not an effect
size. This same limitation also existed in the results of acute
phase. Caution should be used when applying these results
in the clinical setting. Secondly, not all of the included stu-
dies were double-blind, randomized, controlled trails. The
Cilostazol for the Prevention of Acute Progressing Stroke
was an open, multicenter, randomized controlled trial [16].
The information of blinding was not available from the
study of Guo et al. [4], which made it difficult to determine
if this trial was double-blinded. Finally, all of the patients
from the included studies were of Asian descent, suggesting
a limited confidence when applying this data to other popu-
lations. While aspirin was an ideal option for the secondary
prevention of stroke in western countries, it did not seem
suitable for those of Asian descent [5]. Previous studies
have reported that Asians are at a higher risk forside effects
including recurrent ischemic and hemorrhagic strokes in
the secondary stroke prevention phase [5]. Genetic factors
in different race-ethnicities, as independent predictors of
cerebrovascular disease, maybe the main reason for high
risk of side effects in Asian population [34-36]. In addition,
higher and poorer control of blood pressure in Asians may
be another factor contributing to the poor efficacy of as-
pirin in secondary stroke prevention [5]. Hence, cilostazol
might be a safer option for Asians because of its reduced
risk of intracerebral hemorrhage when compared to aspirin.
All of these limitations were considered in the evaluating
the quality of evidence.
Conclusion
Cilostazol therapy played a crucial role in the secondary
prevention of ischemic stroke in chronic phase. No signifi-
cant difference was presented in ROCI between cilostazol
and aspirin, but cilostazol was deemed to be safer. Pro-
spective large RCTs will provide more evidence for cilos-
tazol as an alternative drug for aspirin in secondary
prevention of stroke.
Appendix
1. (cilostazol [Title/Abstract] OR pletal [Title/Abstract]
OR pletaal[Title/Abstract] OR OPC 13013 [Title/
Abstract] OR OPC 21 [Title/Abstract])
2. (aspirin [Title/Abstract] OR acetylsalicylic acid [Title/
Abstract] OR acetyl salicylic acid[Title/Abstract] OR
acetosalicylic acid [Title/Abstract] OR placebo [Title/
Abstract])
3. (ischemi* [Title/Abstract] OR stroke [Title/Abstract]
OR cerebrovascular [Title/Abstract] OR intracerebral
[Title/Abstract] OR embolism [Title/Abstract] OR
thrombosis [Title/Abstract])
4. 1 AND 2 AND 3
5. Limit 4 to humans
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